Genpharmasec
GENERICPHARMASECLTD NSE
Genpharmasec
Commercial ServicesNSE: GENERICPHARMASECLTD BSE: 531592 Trading & Distributors
Key Fundamentals
MicrocapTrading & DistributorsCommercial ServicesMarket Cap
₹65.86 Cr
Volatility
Moderate
P/E Ratio
-116
EBITDA
₹1.22 Cr
Return on Equity
1.89%
Debt to Equity
0.53
Book Value
₹1.2
EPS
₹0
52W High
₹2.15
52W Low
₹0.75
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
4- Stock is trading at 0.98 times its book value
- Company is expected to give good quarter
- Debtor days have improved from 111 to 76.3 days.
- Company's working capital requirements have reduced from 136 days to 61.1 days
Weaknesses
7- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 30.0%
- Company has a low return on equity of 1.56% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.2.83 Cr.
- Promoter holding has decreased over last 3 years: -30.0%
Growth Rate
Revenue Growth
280% higher than
3Y
Net Income Growth
-116% lower than
3Y
Cash Flow Change
201% higher than
3Y
ROE
-827% lower than
3Y
ROCE
244% higher than
3Y
EBITDA Margin (Avg.)
-90% lower than
3Y
Quarterly Results
| Particulars | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.22 | 7.86 | 6.38 | 10.2 | 5.2 | 6.03 | 8.48 | 14.01 | 12.04 | 32.64 | 39.83 | 55.43 | 49.71 |
| Expenses | 6.01 | 7.89 | 6.37 | 10.21 | 5 | 5.9 | 7.76 | 15.01 | 11.1 | 33.1 | 41.07 | 53.44 | 48.75 |
| Operating Profit | 0.21 | -0.03 | 0.01 | -0.01 | 0.2 | 0.13 | 0.72 | -1 | 0.94 | -0.46 | -1.24 | 1.99 | 0.96 |
| OPM % | 3.38% | -0.38% | 0.16% | -0.1% | 3.85% | 2.16% | 8.49% | -7.14% | 7.81% | -1.41% | -3.11% | 3.59% | 1.93% |
| Other Income | 0.06 | 0.15 | 0.14 | 0.31 | 0.57 | 0.75 | 0.81 | 0.94 | 0.69 | 0.46 | 0.98 | 1.02 | 0.37 |
| Interest | 0.06 | 0.07 | 0 | 0.16 | 0.1 | 0.07 | 0.16 | 0.11 | 0.12 | 0.23 | 0.41 | 0.48 | 0.4 |
| Depreciation | 0.01 | 0 | 0.12 | 0.03 | 0.16 | 0.3 | 0.1 | 0.26 | 0.27 | 0.56 | 0.67 | 0.68 | 0.67 |
| PBT | 0.2 | 0.05 | 0.03 | 0.11 | 0.51 | 0.51 | 1.27 | -0.43 | 1.24 | -0.79 | -1.34 | 1.85 | 0.26 |
| Tax % | -420% | 80% | -100% | 345.45% | 35.29% | -39.22% | 40.16% | -37.21% | 2.42% | 48.1% | -37.31% | 27.03% | 165.38% |
| Net Profit | 1.05 | 0.01 | 0.06 | -0.27 | 0.33 | 0.7 | 0.76 | -0.27 | 1.22 | -1.18 | -0.83 | 1.36 | -0.17 |
| EPS in Rs | 0.02 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0.02 | -0.02 | -0.01 | 0.03 | 0 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 26 | 30 | 34 | 140 | 178 |
| Expenses | 25 | 30 | 33 | 139 | 176 |
| Operating Profit | 0 | 0 | 0 | 1 | 1 |
| OPM % | 1% | 0.1% | 0.2% | 0.9% | 0.7% |
| Other Income | 0 | 1 | 3 | 3 | 3 |
| Interest | 0 | 0 | 0 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 2 | 3 |
| PBT | 0 | 0 | 2 | 1 | 0 |
| Tax % | -300% | 168% | 35% | 42% | — |
| Net Profit | 1 | 0 | 1 | 1 | -1 |
| EPS in Rs | 0.02 | 0 | 0.02 | 0.03 | 0 |
| Div. Payout % | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 28 | 55 | 55 | 55 |
| Reserves | -12 | 9 | 10 | 11 |
| Borrowings | 3 | 4 | 5 | 35 |
| Other Liabilities | 1 | 3 | 9 | 37 |
| Total Liabilities | 20 | 71 | 80 | 138 |
| Fixed Assets | 0 | 1 | 8 | 41 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 1 | 19 | 19 | 2 |
| Other Assets | 19 | 51 | 53 | 95 |
| Total Assets | 20 | 71 | 80 | 138 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | -3 | -3 | 3 | -18 |
| Investing | 0 | -28 | -15 | 13 |
| Financing | 3 | 48 | -1 | 4 |
| Net Cash Flow | 0 | 17 | -14 | 0 |
| Free Cash Flow | -3 | -3 | -3 | -21 |
| CFO/OP | -1,277 | -7,275 | 3,825 | -1,357 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 82 | 109 | 148 | 76 |
| Inventory Days | 151 | 133 | 104 | 39 |
| Days Payable | 21 | 36 | 105 | 90 |
| Cash Conversion Cycle | 211 | 207 | 147 | 26 |
| Working Capital Days | 199 | 213 | 133 | 61 |
| ROCE % | — | 2% | 3% | 3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Genpharmasec insights
64 extracted metrics + investor summaries across FY11–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
14 Apr - Genpharmasec says it is not a large corporate under SEBI debt framework as of 14 Apr 2026. 14 Apr - Genpharmasec says it is not a large corporate under SEBI debt framework as of 14 Apr 2026.
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical shares received for demat. 8 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; no physical shares received for demat.
3
Closure of Trading Window
26 Mar - Trading window closed Apr 1, 2026 until 48 hours post audited results for year ended Mar 31, 2026. 26 Mar - Trading window closed Apr 1, 2026 until 48 hours post audited results for year ended Mar 31, 2026.
4
Outcome Of Separate Meeting Of Independent Directors Of The Company.
24 Mar - Independent Directors met 24-Mar-2026; reviewed board and chair performance and information flow; meeting 11:00–11:30. 24 Mar - Independent Directors met 24-Mar-2026; reviewed board and chair performance and information flow; meeting 11:00–11:30.
5
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Feb - Newspaper Publication of Unaudited Financial Result for the quarter ended December 31, 2025. 11 Feb - Newspaper Publication of Unaudited Financial Result for the quarter ended December 31, 2025.
2
Notice Of The 34Th Annual General Meeting Of The Company To Be Held On September 29 2026. 7 Sept 2026
Intimation
Frequently Asked Questions about Genpharmasec
What does Genpharmasec Ltd do?
Incorporated in 1992, Generic Pharmasec
Ltd deals in pharmaceutical activities /services and trades in equity shares[1]
Where is Genpharmasec Ltd (531592) listed?
Genpharmasec Ltd trades as GENERICPHARMASECLTD on the NSE and under code 531592 on the BSE.
Which sector does Genpharmasec Ltd belong to?
Genpharmasec Ltd is classified under the Commercial Services sector, in the Trading & Distributors industry.
What is the market capitalisation of Genpharmasec Ltd?
Genpharmasec Ltd has a market capitalisation of ₹65.86 Cr, which places it in the Small Cap band.
What is the PE ratio of Genpharmasec Ltd?
Genpharmasec Ltd trades at a PE ratio of -116.00, on earnings per share of ₹0, against a book value of ₹1.2 per share.
What is the 52-week high and low of Genpharmasec Ltd?
Over the last 52 weeks Genpharmasec Ltd has traded between ₹0.75 and ₹2.15.
What is the Return on Equity (ROE) of Genpharmasec Ltd?
Genpharmasec Ltd reported a return on equity of 1.89%. Its debt-to-equity ratio is 0.53.
Company Information
Incorporated in 1992, Generic Pharmasec Ltd deals in pharmaceutical activities /services and trades in equity shares[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531592.md for Genpharmasec Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.